Literature DB >> 19823081

DNA-PKcs deficiency in human: long predicted, finally found.

Mirjam van der Burg1, Jacques J M van Dongen, Dik C van Gent.   

Abstract

PURPOSE OF REVIEW: To describe new immunological and molecular findings of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a new candidate gene for radiosensitive T-B-severe combined immunodeficiency (SCID), which has implications for the diagnostic strategy of T-B-SCID. RECENT
FINDINGS: The first human mutation in the gene encoding DNA-PKcs (PRKDC) has been identified in a radiosensitive T-B-SCID patient. A mutation in the DNA-PKcs gene has been predicted for a long time, but spontaneous mutations had only been identified in mouse, horse and dog models.
SUMMARY: DNA-PKcs is a key player in the nonhomologous end joining (NHEJ) pathway of DNA double strand break repair. Correct V(D)J recombination of T cell receptor and immunoglobulin genes is fully dependent on NHEJ, as it is involved in the formation of coding and signal joints. Therefore, a NHEJ defect results in absence of T and B cells. The DNA-PKcs deficient patient presented as a classical SCID patient, not different from a recombination activating gene or Artemis deficiency. The mutation concerned a hypomorphic missense mutation (L3062R) that did not result in absence of protein expression nor in deficient in vivo or in vitro (auto)phosphorylation. Although mutated DNA-PKcs was still able to recruit Artemis to the site of DNA damage, it was probably defective in Artemis activation. In the spontaneous animal models, however, the kinase activity was completely lost, which is essentially different from the human mutation. This observation suggests that some aspects of the DNA-PKcs function are unique to humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19823081     DOI: 10.1097/ACI.0b013e3283327e41

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  26 in total

Review 1.  Choosing the right path: does DNA-PK help make the decision?

Authors:  Jessica A Neal; Katheryn Meek
Journal:  Mutat Res       Date:  2011-03-03       Impact factor: 2.433

Review 2.  Repair of double-strand breaks by end joining.

Authors:  Kishore K Chiruvella; Zhuobin Liang; Thomas E Wilson
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

Review 3.  Quality control of homologous recombination.

Authors:  Ting Liu; Jun Huang
Journal:  Cell Mol Life Sci       Date:  2014-05-25       Impact factor: 9.261

4.  Murine Prkdc polymorphisms impact DNA-PKcs function.

Authors:  Kristin M Fabre; Lila Ramaiah; Ryan C Dregalla; Christian Desaintes; Michael M Weil; Susan M Bailey; Robert L Ullrich
Journal:  Radiat Res       Date:  2011-01-25       Impact factor: 2.841

Review 5.  New frontiers of primary antibody deficiencies.

Authors:  Mirjam van der Burg; Menno C van Zelm; Gertjan J A Driessen; Jacques J M van Dongen
Journal:  Cell Mol Life Sci       Date:  2011-11-01       Impact factor: 9.261

Review 6.  Non-homologous end joining: emerging themes and unanswered questions.

Authors:  Sarvan Kumar Radhakrishnan; Nicholas Jette; Susan P Lees-Miller
Journal:  DNA Repair (Amst)       Date:  2014-02-26

Review 7.  Genetics of SCID.

Authors:  Fausto Cossu
Journal:  Ital J Pediatr       Date:  2010-11-15       Impact factor: 2.638

Review 8.  Diseases associated with defective responses to DNA damage.

Authors:  Mark O'Driscoll
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-12-01       Impact factor: 10.005

9.  DNA-PKcs chemical inhibition versus genetic mutation: Impact on the junctional repair steps of V(D)J recombination.

Authors:  Z Anne Esguerra; Go Watanabe; Cindy Y Okitsu; Chih-Lin Hsieh; Michael R Lieber
Journal:  Mol Immunol       Date:  2020-02-26       Impact factor: 4.407

Review 10.  Directing the use of DDR kinase inhibitors in cancer treatment.

Authors:  Inger Brandsma; Emmy D G Fleuren; Chris T Williamson; Christopher J Lord
Journal:  Expert Opin Investig Drugs       Date:  2017-10-14       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.